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Introduction:Despite its desirable half-life and low energy Auger electrons that travel further than for other radio-
nuclides, 67Ga has been neglected as a therapeutic radionuclide. Here, 67Ga is compared with Auger electron
emitter 111In as a potential therapeutic radionuclide.
Methods: Plasmid pBR322 studies allowed direct comparison between 67Ga and 111In (1 MBq) in causing DNA
damage, including the effect of chelators (EDTA and DTPA) and the effects of a free radical scavenger (DMSO).
The cytotoxicity of internalized (by means of delivery in the form of oxine complexes) and non-internalized
67Ga and 111In was measured in DU145 prostate cancer cells after a one-hour incubation using cell viability
(trypan blue) and clonogenic studies. MDA-MB-231 and HCC1954 cells were also used.
Results: Plasmid DNA damagewas caused by 67Ga andwas comparable to that caused by 111In; it was reduced in
the presence of EDTA, DTPA andDMSO. The A50 values (internalized activity of oxine complexes per cell required
to kill 50% of cells) as determined by trypan blue staining was 1.0 Bq/cell for both 67Ga and 111In; the A50 values
determined by clonogenic assay were 0.7 Bq/cell and 0.3 Bq/cell for 111In and 67Ga respectively. At the concen-
trations required to achieve these uptake levels, non-internalized 67Ga and 111In caused no cellular toxicity. Qual-
itatively similar results were found for MDA-MB-231 and HCC1954 cells.
Conclusion: 67Ga causes asmuch damage as 111In to plasmidDNA in solution and shows similar toxicity as 111In at
equivalent internalized activity per cell. 67Ga therefore deserves further evaluation for radionuclide therapy.
Advances in knowledge and implications for patient care: The data presented here is at the basic level of science. If
future in vivo and clinical studies are successful, 67Ga could becomea useful radionuclidewith little healthy tissue
toxicity in the arsenal of weapons for treating cancer.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Radiopharmaceutical therapies, such as 131I–MIBG, anti-CD20 antibod-
ies (labeled with 90Y or 131I), and 177Lu-Octreotate, have become standard
in the clinic. These beta particle-emitting treatments, however, are general-
ly not curative and can cause toxicity to healthy tissue due to the long range
(up to 1 cm for 90Y) by high beta energies. Radioisotopes emitting Auger
electrons with a much shorter range (b1 μm) are now being considered
for targeted radionuclide therapy and could become useful tools in
targetingmicrometastases that play a detrimental role in tumor recurrence.
Gamma camera imaging with 67Ga has been used regularly in the
clinic since the 1980s to image lymphomawhere itwas useful in disease
staging, monitoring disease progression and relapse, and predicting
therapy response [1]. In Hodgkin's disease, the detection sensitivity is
70 to 83% [2]. Innon-Hodgkin's lymphomathedetectionsensitivitydepends
on cell differentiation status; less differentiated cells show higher avidity for
gallium [1]. Other gallium-avid cancers include lung cancer, melanoma and
multiple myeloma [1,2]. In these applications 67Ga is administered as 67Ga-
citrate and 67Ga uptake by cells is believed to be transferrin-mediated [3], al-
though there is alsoevidence for transferrin-independentmechanisms [4–6].
A feature of 67Ga is that besides its gamma emissions for scintigra-
phy and SPECT imaging, it also emits Auger electrons [7] and thus has
potential as a therapeutic radionuclide. As such it could form part of a
“theranostic pair” with the generator-produced positron emitter 68Ga.
Despite producing fewer Auger electrons per decay (average of 4.7)
than fellow Auger electron emitter 111In (14.7), the average total
Auger electron energy released per decay of 67Ga (6.3 keV) is similar
to that of 111In (6.8 keV) [8]. In fact, amongst Auger electron emitters,
67Ga produces amongst the most energetic (7 to 9 KeV) and longest
ranging (up to 2.4 μm in water) Auger electrons [7]. This may reduce
the need for the radionuclide to be localized in speciﬁc subcellular com-
partments in order to be effective.
67Ga has been explored previously, to a limited extent, as a radionu-
clide for therapeutic applications [9–13]. In vitro resultswere promising
and showed that treatment with 67Ga diminished clonogenic capacity
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in humanU937 lymphoma cells [9] and inmyeloid leukemic blasts from
acute myeloid leukemia patients [10]. A feasibility study in eight pa-
tients with relapsed acute leukemia was less successful due to the low
cell uptake of 67Ga-citrate [11], which might have arisen in part from
using higher citrate concentrations in the clinical preparations than
used in the in vitro work. Others have explored the therapeutic poten-
tial of 67Ga in lymphoma when coupled to anti-CD74 antibodies
[12,14] or anti-LL1 antibodies [13]. Michel et al. showed that 67Ga was
two to three times more potent than 111In when coupled to anti-CD74
antibodies on the basis of equivalent total disintegrations in the medi-
um per viable cell [12]. Low speciﬁc activities and lack of purpose-
designed gallium chelators and conjugates at that time, however, led
to a lack of further enquiry in this ﬁeld.
In recent years the development of peptides and proteins labeled
with 68Ga, arising from the growing popularity of the 68Ga generator
for positron emission tomography applications, has led to a new gener-
ation of effective bifunctional chelators for gallium [15–25]. For exam-
ple, the trishydroxypyridinone chelator allows radiolabelling of
molecular targeting agents with gallium using fast and simple one-
step procedures [15,20]. The resulting enhanced versatility and range
of potentially useful targeting agents nowpresents an opportunity to re-
consider 67Ga as a targeted therapeutic radionuclide.
Here a comparison is made between 67Ga and the well-
characterized and clinically evaluated radionuclide 111In, which has
been successfully tested preclinically as a therapeutic radionuclide at-
tached to cell surface or intracellular targets [26–28]. 67Ga and 111In
have similar half-lives (78 and 67 h, respectively) and both produce
gamma rays. We used the cell-free pBR322 plasmid assay to directly
compare DNA damage induced by the radionuclides without complica-
tions due to cellular and subcellular barriers, DNA repair mechanisms
and other cellular responses. For the ﬁrst time, the levels of activity
per cell required to achieve signiﬁcant cytotoxic effects was calculated
from viability and clonogenic assays using radiolabelled lipophilic com-
plexes in three prostate and breast cancer cell lines, selected for their
possible future use in in vivo models for radionuclide therapy of circu-
lating tumor cells and micrometastases using Auger electron emitters.
2. Materials and methods
2.1. Radionuclide preparation
111In-chloride (111InCl3) (Mallinckrodt, Netherlands) was supplied
at 111 MBq in 0.3 mL 0.05 M HCl. 67Ga-citrate (6.46 mM citrate,
Mallinckrodt, Netherlands) was converted to 67Ga-chloride (67GaCl3)
[29]. Brieﬂy, 67Ga-citrate (82–160 MBq in 2.2 mL) was diluted to 5 mL
with dH2O and passed through a Silica Light SEP-PAK column (Waters,
US) at 1 mL/min. After washing with 5 mL dH2O, trapped 67Ga was
eluted with 0.1 M HCl (Sigma, UK) and collected in 0.5 mL fractions.
Fractions with the highest activity concentration 67Ga-chloride
(200–800 MBq/mL, fractions 6 or 7) were used.
2.2. Cell-free DNA damage by 111In and 67Ga
125 ng pBR322 (10 μL supplied in 10 mM Tris–HCl (pH 8.0) with
1 mM ethylenediaminetetraacetic acid (EDTA), Sigma) was mixed
with 1 MBq 111In-chloride, 67Ga-chloride or 67Ga-citrate and incubated
up to 72 h at 4 °C (ﬁnal EDTA concentration 0.1 mM). The ﬁnal volume
was 100 μL in Dulbecco's phosphate-buffered saline pH 7.4 (PBS; Ther-
mo Fisher, UK).
Plasmids were co-incubated with 14 mM dimethylsulfoxide
(DMSO), excess EDTA (5 mM) or diethylenetriamine pentaacetic acid
(DTPA; 5 mM). Controls included untreated plasmid (no radionuclide),
external irradiation (where radionuclides in a 50 mL tube were physi-
cally separated from plasmid in 1.5 mL microcentrifuge tube inside
the 50 mL tube), and equivalent amounts of non-radioactive gallium-
(0.69 pmol) and indium-chloride (0.58 pmol) at molar concentrations
equivalent to 1 MBq radionuclide.
After treatment, 12.5 ng plasmid on a 0.8% agarose gel, run at 100 V
for 25min, was visualized with Gel Red™ (Biotium, USA) by UV transil-
luminator (Gel Doc-it, BioRad, UK).
2.3. Analysis of gel electrophoresis images
Images were analyzed by densitometry of each plasmid band
(Figs. 1-2, S1–3; supercoiled, circular and linear; Image J 1.48, NIH,
USA). Background was measured and subtracted from band intensity.
The fraction of supercoiled plasmid (undamaged) of total plasmid rep-
resents undamaged plasmid.
2.4. 111In- and 67Ga-oxinate complex synthesis
Lipophilic complexes were prepared from 67Ga citrate as described
previously [30]. 67Ga citrate (Mallinckrodt Medical Inc., Netherlands;
20–50 MBq, 0.1–1 mL) was added to 50 μg oxine (8-hydroxyquinoline;
dissolved in ethanol at 1 mg/mL; Sigma). The solution was extracted
into dichloromethane (Sigma, USA) and this fraction separated and
evaporated to dryness and reconstituted in 2% ethanol in saline.
Tropolone (2-hydroxy-2,4,6-cycloheptatriene-1-one) (Sigma) was
dissolved in ethanol (1 mg/mL). MPO (2-mercaptopyridine-N-oxide)
(Sigma) was dissolved in distilled water at 1 mg/mL. 67Ga citrate
(Mallinckrodt Medical Inc., Netherlands) was added at 20–50 MBq
(0.1–1 mL) to the ligand solution (50 μg tropolone and 500 μg MPO).
The resulting solutions were extracted into dichloromethane (Sigma,
USA) and measured for labeling yield following drying.
Up to 75 MBq 111In-chloride (0.1–0.2 mL), adjusted to pH 6 with ac-
etate buffer, was added to oxine (1 mg/mL in 2% ethanol) and vortexed
for 5 min. 111In-oxine complex was extracted into chloroform, evapo-
rated and reconstituted in 2% ethanol in saline [31].
Radiochemical yield of radiometal complexes was measured in a
dose calibrator.
2.5. Cell culture
Human prostate cancer cells DU145, courtesy of Dr. Florian
Kampmeier [32], and breast cancer cells HCC1954, were grown in
RPMI-1640 at 37 °C in a humidiﬁed atmosphere with 5% CO2. Human
breast cancer cells MDA-MB-231 were grown in Dulbecco's Modiﬁed
Eagle Medium (DMEM; with high glucose 4.5 g/L; PAA, Austria).
Media were supplemented with L-glutamine (1.5 mM; PAA Laborato-
ries, Austria), 10% fetal bovine serum (Invitrogen) and penicillin (50
I.U./mL)/streptomycin (50 μg/mL) (Invitrogen). Prior to use, cells were
trypsinised and washed twice with PBS.
2.6. Cellular uptake and retention of radionuclide oxine complexes
Cells (106) in suspension were incubated with 0.1 MBq 67Ga- or
111In-oxine in 1 mL PBS for 1 h at 37 °C and 5% CO2, then pelleted and
washed twice with PBS. Cell-bound (pellet) and free (supernatant) ac-
tivity was measured by gamma counter.
For cellular retention studies, cells were treated and washed as
above and plated in a 6-well plate for three days. At different times,me-
dium was collected, cells washed, and the amount of cell-bound versus
free activity measured. The percentage of cell-bound activity retained
within the cell at time points after 1 h (set at 100%) was measured.
2.7. Viability assay
Cells (2.5 × 105) were incubated with 67Ga- (2–25 MBq/mL) or
111In-oxine (0.5–30 MBq/mL) in medium (250 μL total) at 37 °C for
1 h. Oxine and ethanol concentrations were 7 μM and 1%, respectively.
Controls included 67Ga-citrate and 111In-chloride (no signiﬁcant uptake
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in cells) and decayed oxine complexes at levels equivalent to complete
decay of 20 MBq/mL samples.
Following incubation, cells were centrifuged, washed and seeded
in medium in 6-well plates for 3 days at 37 °C in 5% CO2. Cells were
then washed, trypsinised and counted for viability by trypan blue
exclusion.
2.8. Clonogenic survival
Cells were treated as in the viability assay, but after treatment and
washing, 800–2500 cells were seeded in 6-well plates at 37 °C in 5%
CO2 for 10–14 days. Medium was replaced every 3 days. Colonies (N50
cells) were ﬁxed, stained with methanol/1% crystal violet (Sigma, 1:1)
and counted. The results were plotted as the surviving percentage rela-
tive to untreated values, with the latter set at 100%.
2.9. Statistical analysis
For plasmid studies, data were analyzed by 2-way ANOVA. Student
and paired t-tests were used to compare preparations at any one partic-
ular time point or the results from the oxine studies, respectively. Statis-
tical analyses were carried out with GraphPad Prism 5 (version 5.04,
GraphPad Software Inc., USA).
3. Results
3.1. Cell free plasmid DNA damage by 111In and 67Ga
Incubation of pBR322 supercoiled DNA with 111In and 67Ga (0.1-
1 MBq) led to single and double DNA strand breaks, i.e. conversion of
supercoiled plasmid to either relaxed or linear plasmid, respectively.
Plasmid integrity (i.e. the fraction of plasmid remaining in the
Fig. 1. A: Representative image of pBR322 on an agarose gel following treatment with a radionuclide. Here, pBR322 was incubated with 1 MBq 111In-chloride (111In-Cl3 or as external
radiation (111In (external)) for 72 h in the presence or absence of DMSO or cold indium chloride (InCl3). B and C: Fraction of supercoiled (undamaged) plasmid, as measured from gels
such as A. Plasmids were incubated with either 111InCl3 (B) or 67GaCl3 (C). Data points are average ± standard deviation (SD; n = 2–3). Relaxed bands represent single strand breaks;
linear bands are double strand breaks.
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supercoiled form) decreased as radioactivity increased; Fig. 1A; Fig. S1).
As this activity produced signiﬁcant damagewithout assay saturation, it
was deemed suitable for comparative studies. DNA damage was detect-
ed as early as 4 h post incubation (Fig. 1B–C) and after 24 h of incuba-
tion, the supercoiled DNA fractions were reduced to 0.001 ± 0.002
and 0.06 ± 0.01 for 67Ga and 111In respectively (p = 0.002 compared
to untreated). In contrast, untreated controls (0.76 to 0.90) and non-
radioactive In-chloride (5.8 nM; 0.89 ± 0.002) or Ga-chloride
(6.9 nM; 0.86 ± 0.04) controls produced little DNA damage.
Plasmid DNAwas partially protected against 111In-induced damage,
and less so from 67Ga, by co-incubation with DMSO (Figs. 1 and S2). At
24 h, DMSO co-incubation led to supercoiled fractions of 0.47 ± 0.13
and 0.20 ± 0.04, for 1 MBq 111In and 67Ga, respectively.
External irradiation (i.e. radionuclide separated from the plasmid by
the walls of a plastic tube; so that only gamma photons were incident
upon the plasmid-containing solution) produced relatively little DNA
damage for 67Ga (p N 0.05 at 48 h compared to untreated controls). Ex-
ternal 111In produced signiﬁcantly more DNA damage than untreated
controls (p b 0.05 at 48 h), but signiﬁcantly less than internal 111In-
chloride with and without DMSO (p b 0.001 and p b 0.001 at 48 h,
respectively).
The addition of chelating agents EDTA, DTPA and citrate provided
partial protection of DNA against damage by both radionuclides
(Figs. 2, S3). At 72 h, 67Ga-chloride plus EDTA or DTPA (5 mM) gave a
supercoiled fraction of 0.18 ± 0.05 or 0.51 ± 0.03, respectively, com-
pared to 0.02 ± 0.02 for 67Ga-chloride only (Fig. 2B). Similarly, 67Ga-
citrate produced less DNA damage (supercoiled fraction: 0.72 ± 0.02)
than 67Ga-chloride. Incubation with 111In-chloride plus additional
EDTA or DTPA led to supercoiled fractions of 0.27 ± 0.08 or 0.62 ±
0.05, respectively, compared to 0.02 ± 0.02 for 111In-chloride alone
(Fig. 2A).
3.2. Radionuclide oxine synthesis
Radiolabelling yields for 67Ga-oxine, -tropolone, and -MPO were
92%, 80%, and 25%, respectively, and 98% for 111In-oxine.
3.3. Binding and retention of radionuclide oxine complexes
67Ga-oxine gave the highest cell binding (Fig. S4); all subsequent
studies were carried out with the oxine complex. In DU145 cells, a
one-hour incubation with 111In-oxine or 67Ga-oxine allowed radionu-
clide binding at 60.6 ± 8.8% or 7.5 ± 1.3%, respectively (Fig. 3A). This
decreased with time with only 31.2 ± 1.4% and 38.8% ± 0.7% of the
initially-bound 111In and 67Ga, respectively, retained 72 h after a one-
hour incubation period (Fig. 3B). Similar results were found in cell
lines MDA-MB-231 and HCC1954 (Figs. S5, S6). The different cell label-
ing efﬁciencies of 111In-oxine and 67Ga-oxine raise the issue of whether
to discuss cellular toxicity in relation to the radioactivity to which the
cells are exposed in total (i.e. the radioactivity added to the culture) or
the radioactivity that is accumulated in the cells (referred to as “cell-
bound” activity henceforth). Both are discussed together in the follow-
ing paragraphs.
3.4. Trypan blue viability assay
A50 is deﬁned as the cell-bound activity causing 50% reduction in vi-
ability relative to untreated cells (100%). Three days after an initial one-
hour incubation period with 67Ga-oxine, the A50 was approximately
1 Bq/cell (Table 1, Fig. 4A). Cell-bound 67Ga activity required to reduce
viability to 17.4± 6.6%was approximately 1.5 Bq/cell; this required in-
cubation with 15 MBq/mL 67Ga-oxine (Fig. 4B). At this concentration,
67Ga-citrate, which was not taken up signiﬁcantly in cells, caused only
53% loss in viability (Fig. 4B). A similar loss in viability occurred in the
control sample incubated with decayed 67Ga-oxine.
Fig. 2. Effect of chelators on plasmid damage treated with 1 MBq 111In-chloride (A) or
67Ga-chloride (B). The amount of supercoiled DNA (undamaged) was measured from
gels where plasmid was incubated with the radionuclide in the presence or absence of
chelators EDTA, DTPA and citrate for up to 72 h. Data points are average ± SD (n = 2–3).
Fig. 3. Cell binding (A) and retention (B) of 0.1 MBq 111In-oxine and 67Ga-oxine in 106
DU145 cells following an initial one-hour incubation. 100% in panel B refers to the
maximum bound radioactivity at one hour (A). Data are average ± SD (n = 3/group).
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Qualitatively similar results were obtained with 111In; the A50 was ap-
proximately 1 Bq/cell. However, even at cell-bound activities up to
19 Bq/cell, viability did not drop below 20%. As for 67Ga, the controls
showed a signiﬁcant level of toxicity caused by decayed 111In-oxine
similar to that caused by 111In-chloride, which did not bind signiﬁcantly
to cells. Interestingly, 67Ga-oxine-induced toxicity at 15 MBq/mL was
the same as that caused by the same concentration of 111In-oxine, de-
spite this concentration of 111In-oxine yielding almost 10-fold higher
activity per cell. Non-cell bound 111In-chloride caused toxicity (viability
around 50%). A similar level of toxicity resulted from the purely chemi-
cal effect of decayed 111In-oxine.
Qualitatively similar results for both 67Ga and 111In were found in
cell lines MDA-MB-231 and HCC1954 (Figs. S7 and S8 and Table S1).
3.5. Clonogenic survival assay
A one-hour incubation period with 67Ga-oxine (15 MBq/mL) with
cellular uptake as little as 1.1 Bq/cell was enough to diminish clonogenic
survival to 4.4% ± 3.1% compared to untreated controls (Fig. 5A). Re-
placing 67Ga-oxine with 67Ga-citrate at this same concentration, with
minimal cellular uptake, caused no signiﬁcant loss in clonogenicity
compared to untreated controls (Fig. 5B). Qualitatively similar results
were obtained for 111In demonstrating that neither radionuclide affect-
ed clonogenicity signiﬁcantly unless bound to the cell (Fig. 5B). Fully
decayed radioactive 67Ga-oxine and 111In-oxine added to the incubation
medium led to a signiﬁcant decrease in relative clonogenic survival
(to 74± 17% and 69± 20% for decayed 67Ga-oxine and 111In-oxine, re-
spectively, see Fig. 5B) compared to untreated controls. However this
chemical toxicity was much less than the toxicity of their non-decayed
counterparts, indicating that the radioactivity was by far themajor con-
tributor to the observed toxic effect. Qualitatively similar results were
found in cell lines MDA-MB-231 and HCC1954 (Figs. S9 and S10 and
Table S2).
4. Discussion
The plasmid data presented here suggest the involvement of differ-
ent mechanisms of DNA damage. These include ionization and forma-
tion of free radicals along the tracks of Auger electrons, local
ionization events caused directly by the residual ion after Auger electron
emission (short range effects), free radicals diffusing signiﬁcant dis-
tances from the Auger electron track and residual ion, andminor ioniza-
tion and free radicals caused by gamma photons (long range effects).
DNA damage produced by 67Ga was signiﬁcantly reduced by chela-
tion with EDTA, DTPA or citrate and incubation with hydroxyl radical
scavenger DMSO. The protective effect of chelating the radionuclides
with EDTA, DTPA or citrate, on DNAmay be a distance effect; assuming
unchelated positively-charged In3+ and Ga3+ bind directly to negative-
ly charged DNA, as has previously been shown for 111In [33].
Complexing 67Ga with EDTA, forming a negatively charged 1:1 6-
coordinate complex, would completely envelope the 67Ga atom,
preventing metal coordination by plasmid DNA [34]. However, 111In
Table 1
Cell-bound activity per cell (Bq/cell) required for a 50% (A50) and 90% (A10) reduction in
viability and clonogenicity in DU145 cells compared to untreated cells (determined by in-
terpolation of data in Figs. 4A and 5A).
A50 (Bq/cell) A10 (Bq/cell)
67Ga-oxine 111In-oxine 67Ga-oxine 111In-oxine
Viability (Trypan blue) 1.0 1.0 1.5 N/A
Clonogenic 0.3 0.7 1.0 0.9
No A10 value exists for 111In-oxine (viability assay), as loss of membrane integrity was not
achieved in more than 75% of cells.
Fig. 4.Viability (trypan blue) of DU145 cells treatedwith 111In-oxine or 67Ga-oxine at 72h.
A: Viability with increasing cell-bound activities (Bq) per cell. B: Controls for radionuclide
oxine treatment: untreated cells, non-cell-bound radioactivity and decayed oxine
complexes, standardized at 15 MBq/mL, inducing cellular uptake of 9.09 ± 1.33 Bq/cell
for 111In-oxine and 1.12 ± 0.20 Bq/cell for 67Ga-oxine groups. Data are average ± SD
(n = 3/group).
Fig. 5. Clonogenic assay of DU145 cells treated with 111In-oxine or 67Ga-oxine. A:
Clonogenicity with increasing cell-bound activities (Bq) per cell. B: Controls for
radionuclide oxine treatment: untreated cells, non-cell-bound radioactivity and decayed
oxine complexes, standardized to treatment at 15 MBq/mL, achieving uptake of 9.09 ±
1.33 Bq/cell for 111In-oxine and 1.12 ± 0.20 Bq/cell for 67Ga-oxine groups. Data are
average ± SD (n = 3/group). Clonogenicity for 111In-oxine at 0.28 ± 0.48% is not visible
on the graph.
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forming a 1:1 complexwith EDTAwould leave some possibility for DNA
to coordinate directly to the radiometal which would remain
coordinatively unsaturated because of its larger ionic radius [35].
DTPA offers more protection than EDTA against DNA damage by 111In
(Fig. 2); this may be because being octadentate it more completely
ﬁlls the coordination sphere of indium than EDTA does [36]. The degree
of protection (EDTA b DTPA b citrate2) is also in line with the negative
charge of the resulting complex: (1-, 2-, 5-).
Free radical scavengers such as DMSO are unlikely to protect
against the short-range effects. Previous studies with free radical scav-
engers have focused on 125I, where DMSO reduced strand breakage by
40% if 125Iwasnot bound to DNA.When bound to DNA, damage induced
by 125I was not diminished by DMSO [37]. Also, non-plasmid-bound
99mTcO4− caused several fold lower induction of single strand breakage
in the presence of DMSO [38,39].
Overall, direct incubation of radionuclides with plasmid DNA in a
cell-free system is useful to understand DNA damage by radionuclide
emissions and decay only. However, in these experiments radionuclides
can directly bind DNA, thus overestimating the potential damage com-
pared to the cellular environment, where direct binding to DNA is less
likely.
Results obtained in cell studies showed that 111In and 67Ga induced
high clonogenic toxicity only if incorporated into the cell; external ra-
dionuclides and other variables had little effect. Nonetheless decayed
radionuclides, producing amongst other compounds zinc and cadmium,
did inﬂuence both viability and clonogenicity. External irradiation via
gamma emissions produced more DNA damage for 111In-chloride
than 67Ga-chloride due perhaps to higher gamma ray exposure rate
constants. Surprisingly, cell viability was decreased for non-
internalized 111In (60.9 ± 8.4%) and 67Ga (47.2 ± 8.4%) compared to
untreated cells, while clonogenic toxicity was not. This highlights that
they measure different aspects of cytotoxicity and are complementary
rather than alternative methods.
The clonogenic toxicity of incorporated radioactivity is similar for
the two radionuclides and for all three cell lines, with an A10 of approx-
imately 1 Bq/cell. This similarity should be interpreted cautiously, since
the cellular toxicity of Auger electron emitters is likely to be highly de-
pendent on the intracellular distribution of the radionuclides, which
we have not determined andwhichmay not be the same for the two ra-
dionuclides. Nevertheless thisﬁguremay be a useful guide to howmuch
radioactivity must be incorporated into cancer cells in vivo for effective
targeted radionuclide therapy (tRT) and could be used to assess feasibil-
ity of clinical tRT.
It should be noted that 67Ga-oxine is not a very effective method of
incorporating 67Ga into cells. Results were, however, consistent with
previous trends, including radiolabeling yields for oxine with 67Ga
[30] and cell labeling numbers of 111In-oxine [31] and 67Ga-oxine [40].
Efﬁcient cell labeling with 111In is probably due to 111In-oxine diffusing
into the cell cytoplasm anddissociatingwhereupon 111In binds intracel-
lular macromolecules and is trapped within the cell [31]. In leukocytes,
111In-oxine also partly localizes to the nucleus [41]. If 67Ga-oxine forms
amore stable complex [40], the radionuclide may diffuse in but become
trapped less readily due to slower dissociation. In order to achieve com-
parable cellular uptake (Bq/cell), the radioactive concentration of 67Ga-
oxine was increased compared to 111In-oxine.
Future studies should focus on targeted approaches aswell as in vivo
therapeutic studies comparing 67Ga with 111In as well as beta emitters
such as 177Lu. Interestingly, the higher energy Auger electrons emitted
by 67Ga compared to other Auger electron-emitting radionuclides may
provide an advantage by relaxing the requirement for 67Ga to be local-
ized in speciﬁc sub-cellular compartments (in particular the nucleus)
in order to be effective as a therapeutic. The critical observation that
67Ga (and similarly 111In) has to be cell bound to be effective suggests
that future targeting studies can focus on the feasibility in vivo of
achieving target uptake of around1 Bq per cancer cell required for effec-
tive cell killing.
5. Conclusion
67Ga damages plasmid DNA in a manner that may be dependent on
distance to theDNA,which in turnmaybe affected by the chemical form
of the radionuclide. Neither 67Ga nor 111In showed substantial toxicity
unless incorporated into the cells. The threshold cellular uptake of
67Ga to achieve substantial cell kill is of the order of 1 Bq per cell. 67Ga
deserves further evaluation for radionuclide therapy, especially in the
context of a theranostic pairing with 68Ga.
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